# The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes

Alessandra Malato<sup>1</sup>, Francesco Dentali<sup>2</sup>, Sergio Siragusa<sup>1</sup>, Francesco Fabbiano<sup>3</sup>, Yoan Kagoma<sup>4</sup>, Maria Boddi<sup>5</sup>, Gian Franco Gensini<sup>5</sup>, Adriano Peris<sup>6</sup>, Mark Crowther<sup>7</sup>, Mariasanta Napolitano<sup>1</sup>

<sup>1</sup>Chair and Unit of Haematology and Transplantation, University Hospital of Palermo, Palermo; <sup>2</sup>Department of Internal Medicine, University of Insubria, Varese; <sup>3</sup>Division of Haematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy; <sup>4</sup>Applied Science and Engineering, University of Toronto, Toronto, Canada; <sup>5</sup>General and Specialist Medicine, Medical and Surgical Critical Care Department, Careggi University Hospital, Florence; <sup>6</sup>Anaesthesia and Intensive Care Unit of the Emergency Department, Careggi University Hospital, Florence, Italy; <sup>7</sup>Department of Medicine, McMaster University, Hamilton, Canada

**Background**. Critically ill patients appear to be at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism during their stay in the intensive care unit (ICU). However, little is known about the clinical course of venous thromboembolism in the ICU setting. We therefore evaluated, through a systematic review of the literature, the available data on the impact of a diagnosis of DVT on hospital and ICU stay, duration of mechanical ventilation and mortality in critically ill patients. We also tried to determine whether currently adopted prophylactic measures need to be revised and improved in the ICU setting.

**Materials and methods**. MEDLINE and EMBASE databases were searched up to week 4 of June 2012. Two reviewers selected studies and extracted data. Pooled results are reported as relative risks and weighted mean differences and are presented with 95% confidence intervals (CI).

**Results**. Seven studies for a total of 1,783 patients were included. A diagnosis of DVT was frequent in these patients with a mean rate of 12.7% (95% CI: 8.7-17.5%). DVT patients had longer ICU and hospital stays compared to those without DVT (7.28 days; 95% CI: 1.4-13.15; and 11.2 days; 95% CI: 3.82-18.63 days, respectively). The duration of mechanical ventilation was significantly increased in DVT patients (weighted mean difference: 4.85 days; 95% CI: 2.07-7.63). DVT patients had a marginally significant increase in the risk of hospital mortality (relative risk 1.31; 95% CI: 0.99-1.74; p=0.06), and a not statistically significant increase in the risk of ICU mortality (RR 1.64; 95% CI: 0.91-2.93; p=0.10).

**Conclusions**. A diagnosis of DVT upon ICU admission appears to affect clinically important outcomes including duration of ICU and hospital stay and hospital mortality. Larger, prospective studies are warranted.

Keywords: deep vein thrombosis, critically ill patients, outcomes, meta-analysis.

# Introduction

Critically ill patients are at high risk of developing venous thromboembolism (VTE) during their stay in the intensive care unit (ICU) because of the presence of several risk factors including premorbid medical and surgical conditions, invasive tests and treatments, prolonged immobility (often exacerbated by sedation or paralysis), vascular injury from indwelling central venous catheters, and acute and chronic renal insufficiency<sup>1</sup>. In addition, critical illness activates the coagulation cascade which may mediate the increased likelihood of VTE<sup>2-5</sup>. Thus, even when adequate antithrombotic prophylaxis is used, deep vein thrombosis (DVT) may occur in up to 10% of patients<sup>6</sup>. VTE in critically ill patients may be associated with significant morbidity, including prolonged requirement for ICU and hospital stay and, potentially, increased mortality<sup>7</sup>.

The diagnosis of DVT and pulmonary embolism (PE) in critically ill patients is, for many aspects, problematic. The performance and interpretation of diagnostic tests for VTE, in particular for PE, in such patients is not well defined: critically ill patients frequently receive mechanical ventilation which reduces the utility of ventilation-perfusion lung scanning, they often have impaired renal function which may preclude intravenous contrast-based testing such as venography or computed tomography pulmonary angiography, the

use of pulmonary end-expiratory pressure may cause "false positive" venous ultrasounds, while large central venous catheters may impede blood flow and simulate a thrombus<sup>7</sup>.

Recent studies suggest that the prevalence of DVT on admission to a medical-surgical ICU may be as high as 10%, and that the incidence of DVT developing during the ICU stay (based on systematic screening) ranges from 8% to 40% <sup>6</sup>. These patients have an increased risk of developing PE. Unfortunately, only a few studies have systematically evaluated the incidence of PE in medicalsurgical patients with DVT. In a recent, relatively small study on ICU patients, 50% of patients with proximal lower limb DVT and 20% of patients with symptomatic upper limb venous thrombosis have asymptomatic PE at presentation<sup>8</sup>.

Although multiple criteria for the detection of early DVT have been developed, there is no consensus on the best method of screening and prevention in critically ill patients.

In contrast to the extensive documentation on the short and long-term outcomes of patients with DVT evaluated in other clinical settings, little is known about the clinical course of this disease in the ICU setting. The occurrence of DVT in ICU seems to be a prognostic marker of severity, although its causal relationship with the outcome is not well defined according to available studies. A comprehensive review of data could provide information to support the improvement of prophylactic measures, whether medical and/or mechanical, in order to avoid this frequent complication. Thus, to acquire additional evidence on the real impact of DVT in critically ill patients, we performed a meta-analysis of data available in the literature.

We hypothesized that both clinically undetected and clinically evident VTE would affect the prognosis of critically ill patients.

# Materials and methods Study identification

A systematic search of MEDLINE (1946 to week 4 of June 2012), EMBASE (1980 to week 27 of 2012) was performed using the search terms "DVT", "venous thrombosis", "venous thromboembolism", "ICU", "intensive care unit", "medical-surgical ICU", "quality of life", "hospitalization length", "ICU stay", "hospitality mortality " "duration of mechanical ventilation", "ICU mortality", and "morbidity" both as medical subject headings and keywords.

#### **Study selection**

Two Authors (AM and YK) independently reviewed all selected titles and abstracts. Studies were excluded if the title and/or abstract was not appropriate for the aim of the current review. Full texts were subsequently obtained for eligible studies or when the relevance of an article could not be excluded with certainty. Disagreement was resolved by consensus and by opinion of a third reviewer (FD), if necessary.

English language studies were included if they met the following criteria:

- (i) the primary outcomes selected were:
  - a) duration of ICU or hospital stay,
  - b) ICU or hospital mortality,
  - c) duration of mechanical ventilation;
- (ii) the population consisted of adults (over 17 years of age) admitted to a medical-surgical ICU with a DVT diagnosed during the hospital stay or at admission to the ICU patients receiving thromboprophylaxis at the time of DVT diagnosis were included in the current analysis;
- (iii) the study design was a prospective/retrospective cohort study or randomised clinical trials that investigated the influence of DVT on one or more of the following outcomes: hospital stay, ICU stay, duration of mechanical ventilation, and mortality. Studies providing outcomes without specific reference to patients with DVT were excluded.

If the required data could not be located in the published report, we attempted to obtain the necessary information by contacting the corresponding author. Studies not reporting the identified outcomes or without clear information on the analysis of the aforementioned outcomes were excluded. Studies were included when data were expressed as medians and interquartile ranges instead of means  $\pm$  standard deviations. Patients with PE but without a documented DVT were excluded. The current analysis is focused mainly on DVT because PE is difficult to identify in patients in ICU. Finally, studies on patients with acute spinal cord injury or those who underwent neurosurgery were excluded. To assess the agreement between reviewers for study selection, we used the k statistic, which measures agreement beyond chance<sup>9</sup>.

#### **Data extraction**

Two investigators (AM and FD) independently extracted data from each study. Information on study characteristics, population characteristics and outcomes was extracted. Only cases of DVT were analysed. The outcomes evaluated in ICU patients with and without DVT were duration of mechanical ventilation, ICU stay and hospital stay, and total ICU and hospital mortality. Studies in which outcomes data could not be identified for extraction, and studies that evaluated hospitalised medical patients were excluded. Any disagreements between reviewers were resolved through discussion to reach consensus.

Blood Transfus 2015; 13: 559-68 DOI 10.2450/2015.0277-14

#### Assessment of study validity

The same two unmasked investigators independently completed the assessment of study validity. Because the use of quality scoring systems or quality scales in observational studies is controversial<sup>10</sup>, we decided to assess study quality based on the type of study (prospective or retrospective) and selection of patients (consecutive enrolment without potential bias of selection). For each item fulfilled one point was given. A total of two points defined high-quality studies; one or less defined a low-quality study.

Given the characteristics of the included studies, the methodological quality of each study was also evaluated with the Newcastle-Ottawa Scale (NOS), which is specifically developed to assess the quality of non-randomised observational studies<sup>11</sup>. The scoring system encompasses the following eight items: clear definition of study sample, selection, interventions, outcomes, adequate assessment of the outcome, analyses for comparability, adequate length of follow-up, and appropriate interpretation of results. If an item was adequately addressed, 1 point each was awarded for the first seven specific items and 2 points for analyses for comparability. This results in a quality score between 0 and 9.

#### Data analysis

The weighted mean proportion of the rate of DVT (prevalence plus incidence) was calculated using a random-effects model. Associations between the presence of DVT and ICU and hospital mortality and the mean difference of duration of mechanical ventilation and of ICU and hospital stay in ICU patients with and without DVT were calculated using a random-effects model (the Der Simionan and Laird method)<sup>12</sup>. Pooled results are reported as odds ratio (OR) and weighted mean difference (WMD) and are presented with 95% confidence interval (CI) and with two-sided probability values. A probability value of 0.05 or less was considered statistically significant.

The appropriateness of pooling data across studies was assessed using the Cochran Q and I<sup>2</sup> test for heterogeneity, which measures the inconsistency across study results and describes the proportion of total variation in study estimates that is due to heterogeneity rather than sampling error<sup>13</sup>. Finally, funnel plots of effect size against standard error were completed, whenever possible, to assess for the presence of publication bias<sup>14</sup>.

We used Review Manager (RevMan; version 5.0 for Windows; Oxford, England; The Cochrane Collaboration, 2008) and Stat Direct software (Version 2.7; StatsDirect Ltd, Cheshire, UK) to pool data.

# Results

#### Study identification and selection

We identified 926 potentially relevant studies from the following databases: 256 from Medline and 670 from EMBASE (Figure 1). After screening the titles and abstracts, 870 were excluded using the predefined inclusion and exclusion criteria; the remaining 56 studies were retrieved for a more detailed evaluation. Manual review of references revealed two additional studies. Fifty of the 58 studies were subsequently excluded after detailed review of the full texts, leaving eight potentially appropriate articles<sup>15-23</sup>. One study was subsequently excluded since data were not presented in a manner that allowed extraction<sup>15-23</sup>. Therefore, seven studies were included in the current meta-analysis. Inter-observer agreement for study selection was good, with a *k* value of 0.74.

#### **Study characteristics**

Of the seven included studies, five were prospective<sup>17-20,22</sup>, one was retrospective<sup>21</sup> and one study was both prospective and retrospective<sup>16</sup>. Results of the study quality assessment according to the NOS are reported in Table I. The characteristics of the included studies are shown in Table II. DVT was diagnosed using Doppler ultrasonography (DUS) in three studies<sup>20-22</sup>, compression ultrasound (CUS) in three studies<sup>16-18</sup> and in one study it was diagnosed using CUS and/or




Figure 1 - Study progression selection.

 Table I
 - New Castle Ottawa Scale score of the analysed studies.

Study	Score
Ibrahim <sup>21</sup> (2002)	8
Velmahos <sup>22</sup> (1998)	9
Major <sup>20</sup> (2003)	4
Cook <sup>19</sup> (2005)	8
Joynt <sup>17</sup> (2006)	7
Khouli <sup>18</sup> (2009)	5
Boddi <sup>16</sup> (2010)	5

venography<sup>19</sup>. In all the evaluated studies, screening for DVT was done in all patients irrespectively of clinical symptoms or suspicion. In two studies<sup>15,19</sup> routine screening of the lower extremities by CUS was performed within 48 hours of admission to the ICU, in four studies<sup>17,18,20,22</sup> it was done every 7 days or sooner, clinically indicated and in one study<sup>16</sup> screening was performed twice weekly. The study by Major et al. was excluded from this analysis since the presence of DVT was not systematically determined in the entire study population. PE was diagnosed using pulmonary angiography in three studies<sup>19,20,22</sup> ventilation/perfusion lung scan in two studies<sup>19-22</sup> and computed tomography pulmonary angiography in two other studies<sup>19,20</sup>. In contrast to the screening for DVT, these investigations were performed only when there was a clinical suspicion of PE. All seven studies evaluated the efficacy of thromboprophylaxis; unfractionated heparin (UFH) was used in four studies<sup>19-22</sup>, low molecular weight heparin (LMWH) in three studies<sup>17,20,22</sup>, UFH and LMWH in one study<sup>19</sup> and a sequential compression device (SCD) in six studies<sup>16-18,20-22</sup> (Table II). In all these studies, prophylaxis was started on admission to the ICU and continued throughout the ICU stay (thromboprophylaxis was primarily pharmacological, including UFH and LMWH, mechanical prophylaxis included pneumatic compression devices and anti-embolic stockings). The dosage and timing of prophylaxis were not clearly reported in all the analysed studies and it did not allow a specific analysis of this intervention.

#### **Population characteristics**

The number of the subjects enrolled in each study ranged from 110 to 714. The baseline characteristics of the populations are shown in Table IIIa and IIIb. Risk factors that may influence VTE risk, including underlying malignancy and APACHE II score or occurring during ICU stay (mechanical ventilation, use of inotropes/vasopressors and femoral venous catheters) were reported variably and not evaluated by all studies.

A total of 139 episode of DVT were detected in the 1,163 included patients for a mean rate of 12.7% (95% CI: 8.7-17.5%). The rate of DVT was similar when we

excluded studies that evaluated the presence of DVT in ICU populations not receiving pharmacological or mechanical antithrombotic prophylaxis (mean rate 12.0%; 95% CI: 7.8-16.9%).

## Outcomes

Outcomes assessed during ICU stay in patients with and without DVT were tabulated; information on all relevant outcomes could not be obtained from all studies (Table IV).

#### **Duration of mechanical ventilation**

Four studies evaluated the duration of mechanical ventilation<sup>9,10,19</sup> in patients with and without DVT (84 and 670 patients, respectively).

The duration of mechanical ventilation was significantly longer in patients with DVT than in those without DVT (WMD 4.85 days; 95% CI: 2.07, 7.63 days; p=0.006). There was no heterogeneity among the studies (I<sup>2</sup>=0%; p=0.55) (Figure 2A). Due to the low number of studies, funnel-plot analysis could not be done. Publication bias could not, therefore, be assessed.

# Duration of stay in hospital and the intensive care unit

Three studies evaluated the duration of ICU stay and five studies the duration of hospital stay (84 patients with and 487 patients without DVT)<sup>12-14,18,20</sup>.

DVT patients spent a significantly longer time in the ICU than did patients without DVT (WMD 7.28 days; 95% CI: 1.41-13.15 days; p=0.02). Heterogeneity among the studies was moderate, but not significant (I<sup>2</sup>=47.9%; p=0.15) (Figure 2B). Due to the low number of studies, funnel-plot analysis could not be done. Publication bias could not, therefore, be assessed.

Hospital stay was significantly longer in DVT patients than in patients without DVT (WMD 11.2 days; 95% CI: 3.82-18.63 days; p=0.003). Heterogeneity among the studies was significant (I<sup>2</sup>=73%; p=0.005) (Figure 2C,D). Funnel plot of WMD *vs* standard error appeared symmetric, suggesting absence of a publication bias.

#### Intensive care unit and hospital mortality

Five studies evaluated ICU mortality (96 patients with and 1474 patients without DVT)<sup>9,10,17,18</sup>. The data from the study by Boddi *et al.*<sup>16</sup> were not published but were obtained on request from the Authors.

DVT patients had a non-significant increased risk of ICU mortality compared to patients without DVT (RR 1.64; 95% CI, 0.91-2.93; p=0.10). Heterogeneity among the studies was marginally significant ( $I^{2}=53\%$ ; p=0.07) (Figure 2E). Funnel plot of RR versus standard error appeared symmetric, suggesting absence of a publication bias.

	Study design	Methods used for DVT diagnosis	Methods used for PE diagnosis	Number of patients lost to follow-up or withdrawn	Thromboprophylaxis	Dosage and timing	Number of patients in each study	Timing of DVT/ PE screening tests during ICU stay
Ibrahim <sup>21</sup> (2002 )	Retrospective	CUS/DUS	n/a	n/a	UFH/SCD	5,000 IU s.c. twice/daily	110	Every 7 days or sooner as clinically indicated
Velmahos <sup>22</sup> (1998)	Velmahos <sup>22</sup> Prospective (1998)	DUS femoral and popliteal PA and/or	PA and/or V/Q scan	4 with IV or IVC thrombi were excluded from final analysis	LDH/SCD bilateral	5,000 IU every 12 or 8 hours s.c. upon ICU admission	200	Every 7 days or sooner as clinically indicated
Major <sup>20</sup> (2003)	Prospective	DUS. at least every 7 days	PA and/or CT angiogram	2 excluded due to starting s.c. heparin after admission to ICU: 17 died before discharge from ICU	SCD/UFH/LMWH	n/a	726	Every 7 days or sooner as clinically indicated
Cook <sup>19</sup> (2005)	Prospective	CUS and/or venography	V/Q scan, helical CT, PA	22 (7.8%): second admission to ICU, trauma, withdrawal of life support. 71 died in ICU, 103 died in hospital, 10 had active bleeding during the study	UFH s.c and i.v/ LMWH/warfarin/ antiembolic stocking	UFH 5,000 IU s.c. twice daily	261	Within 48 hours of ICU admission, twice weekly, and if DVT/ PE was suspected
Khouli <sup>18</sup> (2006)	Prospective	CUS	n/a	14	UFH, SCD, UFH+SCD	5,000 IU every 8 hours	141	Every 7 days or sooner as clinically indicated
Joynt <sup>17</sup> (2009)	Prospective	CUS and DUS	n/a	'n/a	n/a	n/a	80	Twice weekly
Boddi <sup>16</sup> (2010)	Prospective/ Retrospective	cus	n/a	n/a	LMWH and/or elastic compression stocking	5,000 IU once daily	375	Within 48 hours of ICU admission, and twice weekly until discharge

Deep vein thrombosis in critically ill patients

Blood Transfus 2015; 13: 559-68 DOI 10.2450/2015.0277-14

Study	Sample size	Mean age (DVT vs no DVT)	Similarity between study groups	dy groups	DVT <i>vs</i> no DVT (n.)	Apache II (DVT vs no DVT) Mean±SD		Ventilated (n.)	Isotrope <i>vs</i> Vasopressor (n.)
Ibrahim <sup>21</sup> (2002)	) 110	58.7±16.4	Yes		26 vs 84	21.5±7.5 vs 23.9±8.2		110	n/a
Velmahos <sup>22</sup> (1998)	98) 200	37 years, 40±15.9 vs 37±15.6	5 Yes		26 vs 174	ISS used: 23±13 vs 21.2±10.5		Indirectly measured by PEEP	n/a
Major <sup>20</sup> (2003)	DVT vs no DVT 12/714	37 years, 40±15.9 vs 37±15.6		People with DVT had elevated APACHE/SAPS	12 vs 714	28.5±2.2 vs 16.4±0.3		n/a	n/a
Cook <sup>19</sup> (2005)	261	66.9±15.1	n/a		32 vs 229	25.5±8.4		31 (96.9%) vs 199 (87.7%), p=0.22	22 9 (36%) vs 43 (19.9%)
Khouli <sup>18</sup> (2006)	141	6,4% (<40 years), 96,6% (>40 years)	0 years) Yes		14 vs 127	n/a		n/a	n/a
Joynt <sup>17</sup> (2009)	80	64 (18-78) vs 60 (17-79), p=0	0,87 Yes		15 vs 65	21 (9-29) vs 20 (11-32)	(2)	14 (93%) vs 57 (88%)	n/a
Boddi <sup>16</sup> (2010)	378	61 (46,5-77,5) vs 53 (35-72)	Yes		12 vs 245	n/a		14.5 (6.5-19.75) vs 3 (1.9), p=0.001	01 n/a
lable IIIb -	Table IIIb - Population characteristics (2).	teristics (2).							
Study U)	Underlying malignancy (DVT vs no DVT) (n.)	CVC (DVT vs no DVT) (n.)	Renal failure (DVT vs no DVT) (n.)	Exclusion criteria	criteria		Type of DVT	VT	Event number
Ibrahim <sup>21</sup> 8 (2002)	8 vs 7	17 vs 68	3 us 1	<18 years, <7 days r temporary ICU stay	<7 days mecha ICU stay	<li>4.18 years, &lt;7 days mechanical ventilation/ temporary ICU stay</li>	DVT: uppel calf v (3), p thrombosis PE: 11.5% i	DVT: upper limbs (5), lower limbs (21), calf v (3), proximal to calf (18), occlusive thrombosis (19), catheter (4). PE: 11.5% in pts with DVT.	Prior DVT in pts with DVT: 2 (7.7%). Prior DVT in pts with no DVT: 1 (1.2%)
Velmahos <sup>22</sup> n/a (1998)	5	12 (46%) vs 51 (29%)	'n/a	ISS <16, pt minor or m	ISS <16, pts <12 years, minor or moderate injury		DVT: 3 ext 2 superficia PE: 4 pts cli	DVT: 3 external Iliac, 20 common femoral, 2 superficial femoral, 23 popliteal. PE: 4 pts clinically diagnosed.	n/a
Major <sup>20</sup> n/a (2003)	ņ	n/a	n/a	End stage liv anticoagulat diagnosis of to admissior prophylaxis	End stage liver disease, therapeutic anticoagulation prior to admission, diagnosis of DVT, IVC filter in place to admission or one currently place prophylaxis	End stage liver disease, therapeutic anticoagulation prior to admission, known diagnosis of DVT, IVC filter in place prior to admission or one currently placed for PE prophylaxis	DVT and PE	Ξ.	n/a
Cook <sup>19</sup> n/a (2005)	ß	221 (84.7%) vs 83 (38.4%)	Haemodialysis: 4 (16%) <i>vs</i> 13 (6%)	<18 years, ] support witi trauma or o	<18 years, ICU <72 hours, pre support withdrawal, admitted of trauma or orthopaedic surgery	gnancy, life liagnosis of	DVT: 9 righ 6 bilateral	DVT: 9 right-sided, 10 left-sided, 6 bilateral	Only first
Khouli <sup>18</sup> 3/ (2006) 11	3/15 (20%), 11/126 (9%)	96	n/a	Admission anticoagula contraindic	diagnosis of D ition, major sur, ations to the us	Admission diagnosis of DVT, receiving full anticoagulation, major surgical procedure, contraindications to the use of UFH and SCD	10 proximal, 4 distal	ıl, 4 distal	n/a
Joynt <sup>17</sup> 1 ( (2009)	1 (7%) vs 6 (9%), p=1,0	n/a	0 <i>vs</i> 3	Pregnancy, too un diagnosis of DVT	too unstable fo f DVT	Pregnancy, too unstable for ultrasound, with a diagnosis of DVT	6 proximal, 9 distal	, 9 distal	n/a
Boddi <sup>l6</sup> n/a (2010)	53	n/a	n/a	<18 years, ) ulcer, recen failure, preg congenital o	<18 years, recent DVT, active gastroduc ulcer, recent haemorrhagic stroke, liver failure, pregnancy, severe renal impairm congenital or acquired coagulation.	odenal nent,	Retrospectiv 8 subpoplite 2 bilateral. Prospective	Retrospective: 6 femoral-popliteal veins, 8 subpopliteal, 6 right-sided, 6 left-sided, 2 bilateral. Prospective: 10 proximal, 2 distal.	n/a

Blood Transfus 2015; 13: 559-68 DOI 10.2450/2015.0277-14

All rights reserved - For personal use only No other use without premission

Table IV - Outcomes.

Study	Duration of mechanical ventilation in days (DVT <i>vs</i> no DVT)	Duration of hospitalisation in days (DVT <i>vs</i> no DVT)	ICU stay in days (DVT vs no DVT)	Hospital mortality rate (DVT vs no DVT) [95% confidence interval]	ICU mortality rate (DVT vs no DVT, n.) [95% confidence intervals]
Ibrahim <sup>21</sup> (2002)	18.9±19.7 vs 14.6±12.9, p=0.310	31.4±21.7 vs 27.5±18.2, p=0.375	18.6±14.6 vs 15.9±1.04, p=0.388	8.9 (34.6%) vs 26.8 (32.1), p=0.815	n/a
Velmahos <sup>22</sup> (1998)	Not given^	49±32 vs 31±24, p<0.05	34±31 vs 19±18, p<0.05	n/a	31% (8) vs 18% (31), p= 0.04
Major <sup>20</sup> (2003)	n/a	n/a	n/a	n/a	17% (2) vs 2% (15) p=0.03
Cook <sup>19</sup> (2005)	9** (4-25)* <i>vs</i> 6 (3-13)*, p=0.03	51** (24-73)* <i>vs</i> 23** (12-47)*, p<0.001	17.5** (8.5-30.5)* vs 9** (5,17)*	17 (53.1%) vs 85 (37.4%), p=0.04	-, 8** vs -, 62**, p=0.78
Joynt <sup>18</sup> (2006)	4 [0-14] <i>vs</i> 2 [0-46], p=0.81	0 [0-24] <i>vs</i> 0 [0-57], p=0.73	4 [5-21] <i>vs</i> 3 [2-61], p=0.89	5 (33%) <i>vs</i> 18 (28%), p=0.75	n/a
Khouli <sup>17</sup> (2009)	5.5 [2-20] <i>vs</i> 6 [1-36], p=0.90	n/a	8 [3-23] <i>vs</i> 8 [3-36], p=0.52	17% [5-51] vs 21% [10-23]; p=0.70	n/a
Boddi <sup>16</sup> (2010)	14.5 [6.5-19.75] vs 3 [1-9], p=0.001	n/a	14 [9-26] vs 10 [7-29], p=0.05; 19 [13.5-30] vs 7 [4-15], p=0.001	n/a	n/a

The fourth column (ICU stay in days) reports values as mean ± standard deviation, data on interquartile range (\*) and median (\*\*) are reported in the last four lines. Square brackets report 95% confidence intervals (CI).

\* Interquartile range; \*\* median; ^necessity for ventilation measured by positive end-expiratory pressure; -: missing value. DVT: deep vein thrombosis; vs: versus; ICU: intensive care unit.

Four studies evaluated hospital mortality (87 patients with and 505 patients without DVT)<sup>9,10,17,18</sup> DVT patients had a non-significant increased risk of hospital mortality compared to patients without DVT (RR 1.31; 95% CI, 0.99-1.74; p=0.06). There was no heterogeneity among the studies (I<sup>2</sup>=0%; p=0.88) (Figure 2E). Due to the low number of studies, funnel-plot analysis could not be done. Publication bias could not, therefore, be assessed.

# Discussion

Our systematic review and meta-analysis of the literature confirms that DVT is not uncommon in ICU patients. Although DVT has potentially serious consequences, it is often unrecognised among ICU patients. Unfortunately, physical examination is not useful to rule out a diagnosis of DVT in these patients<sup>24</sup>. Concern about undiagnosed DVT in the ICU is justified by studies showing that 10% to 100% of DVT identified by screening ultrasound were clinically unsuspected, and it is possible that many mechanically ventilated patients with sudden episodes of hypotension, tachycardia, or hypoxia may have undetected PE<sup>25</sup>.

In this analysis, designed to explore the impact of a diagnosis of DVT on clinically important outcomes in the ICU, we were able to pool data from seven studies for a total of about 1,800 patients who met the predefined criteria. Statistically significant differences were found in ICU and hospital stay, duration of mechanical ventilation and hospital mortality between patients or without DVT. Furthermore, hospital mortality appeared to be marginally increased in DVT patients in comparison to patients without DVT. On the other hand, although there was a trend, ICU mortality was not significantly different between the two groups. However, these apparently negative results may be explained by the relatively low number of patients included in our meta-analysis.

Our observations are important because the longer duration of stay and duration of mechanical ventilation contributes to increasing health care costs while higher rates of morbid outcomes, including duration of stay and death, are clearly of importance to patients in the ICU. Interestingly, DVT appears common in critically ill patients, despite the routine use of prophylactic measures, even when applied on admission.

The results of our systematic review may have important implications for clinical practice. In ICU patients, a DVT surveillance protocol may help in early identification of lower limb thrombi and can help in making decisions related to treatment to prevent progression to PE. However, the choice of the best screening test and the time of screening remain to be established. Venography is still considered the gold standard for the diagnosis of DVT, but this test is invasive and is not a cost-effective method for routine evaluation of DVT. Furthermore, the need for transport, positioning and dye exposure make this test problematic for most ICU patients. Ultrasonography is non-invasive and inexpensive<sup>26</sup>. However, the sensitivity of screening ultrasound for venous thrombosis in asymptomatic

(A)		DV	Т		Contro	s		Mean Difference	Mean Difference
Study or Subgroup	Me	ean	SD To	tal Mea	n SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Boddi prospective 201	0 14	.75 8	.61	12 6.8	89 8.78	245	31.0%	7.86 [2.87, 12.85]	
Boddi retrospective 20	10 14	.07 8	.86	14 10.4	46 9.73	112	31.2%	3.61 [-1.37, 8.59]	+
Cook 2005		9 15	.55	32	6 7.4	229	25.8%	3.00 [-2.47, 8.47]	+
Ibrahim 2002	1	8.9 1	9.7	26 14	.6 12.9	84	11.9%	4.30 [-3.76, 12.36]	+
Total (95% CI)			:	84		670	100.0%	4.85 [2.07, 7.63]	•
Heterogeneity: Tau <sup>2</sup> =	0.00: Ch	i <sup>2</sup> = 2.09	). df = 3	(P = 0.5	5);  ² = (	0%			
Test for overall effect:				(	- // -			-	-20 -10 0 10 20
	_ 0	(	,,					F	avours experimental Favours control
(B)	I	DVT			b DVT			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total \	Weight	IV, Random, 95% C	CI IV, Random, 95% CI
Cook 2005	17.5	16.29	32	9	8.88	229	42.1%	8.50 [2.74, 14.26]	— <b>∎</b> —
Ibrahim 2002	18.6	14.6	26	15.9	10.4	84	40.5%	2.70 [-3.34, 8.74]	-+∎
Velmahos 1998	34	31	26	19	18	174	17.4%	15.00 [2.79, 27.21]	—
Total (95% CI)			84			487 <sup>·</sup>	100.0%	7.28 [1.41, 13.15]	•
Heterogeneity: Tau <sup>2</sup> = 1	2.66: CI	hi² = 3 8	34. df =	2 (P =	0.15): F	² = 48%		- / .	
Test for overall effect: Z				- (	<b>.</b> , I	.070			-20 -10 0 10 20
. Socior overall effect. Z	. <u>2.</u> <del>1</del> 0	, – U.I						I	Favours experimental Favours control
(C)		DVT		No [	υντ			Risk Ratio	Risk Ratio
Study or Subgroup	E		Total			l Weig	aht M-	H, Random, 95% CI	
Boddi prospective 2010		3	12	39				1.57 [0.57, 4.36]	
Boddi retrospective 20		3	14	20				1.20 [0.41, 3.53]	<b>_</b>
Cook 2005		8	32	62				0.92 [0.49, 1.75]	
		-						,,	
Major 2003		2	12	15	5 714	1 12.	5%	7.93 [2.03, 30.93]	<b>-</b>
Major 2003 Velmahos 1998		2 8	12 26	15 31				7.93 [2.03, 30.93] 1.73 [0.89, 3.34]	
Velmahos 1998			26		1 174	4 26.2	2%	1.73 [0.89, 3.34]	
Velmahos 1998 Total (95% CI)		8		31	1 174 <b>147</b> 4		2%		• • • • • • • • • • • • • • • • • • •
Velmahos 1998 Total (95% CI) Total events	0.23: Ch	8 24	26 <b>96</b>	31 167	1 174 <b>147</b> 4	4 26.2	2% 0%	1.73 [0.89, 3.34]	
Velmahos 1998 Total (95% CI)		8 24 ni² = 8.5	26 <b>96</b> 55, df =	31 167	1 174 <b>147</b> 4	4 26.2	2% 0%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93]	0.05 0.2 1 5 20 avours experimental Favours control
Velmahos 1998 <b>Total (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: 2		8 24 hi² = 8.5 5 (P = 0	26 <b>96</b> 55, df =	31 167 4 (P =	1 174 <b>147</b> 4 7 0.07); 1	4 26.2 4 <b>100</b> .4 <sup>2</sup> = 53%	2% 0%	1.73 [0.89, 3.34] <b>1.64 [0.91, 2.93]</b> Fa	avours experimental Favours control
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D)	Z = 1.65	8 24 hi <sup>2</sup> = 8.5 5 (P = 0 <b>DVT</b>	26 <b>96</b> 55, df = .10)	31 167 4 (P = C	1 174 1474 7 0.07); 1 Controls	4 26.2 4 <b>100</b> .0 2 <sup>2</sup> = 53%	2% 0%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference	avours experimental Favours control Mean Difference
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D) Study or Subgroup	Z = 1.65 Mean	8 24 5 (P = 0 DVT 5 SE	26 96 55, df = .10) • Total	31 167 4 (P = C <u>Mean</u>	1 174 1474 7 0.07); I Controls	4 26.4 100. <sup>2</sup> = 53% <u>Total</u>	2% 0% 	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% (	Mean Difference IV, Random, 95% CI
Velmahos 1998 <b>Total (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: 2 (D) <u>Study or Subgroup</u> Boddi prospective 2010	Z = 1.65 <u>Mean</u> 21.33	8 24 ni <sup>2</sup> = 8.5 5 (P = 0 <b>DVT</b> 5 <b>SE</b> 3 9.63	26 96 55, df = .10) <u>Total</u> 5 12	31 167 4 (P = C <u>Mean</u> 10.91	1 174 1472 7 0.07); 1 Controls <u>SD</u> 10.1	4 26.3 ↓ <b>100</b> .1 <sup>2</sup> = 53% <u>Total</u> 245	2% 0% 6 <u>Weight</u> 25.0%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% ( 10.42 [4.83, 16.01]	Mean Difference IV, Random, 95% Cl
Velmahos 1998 <b>Total (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D) <u>Study or Subgroup</u> Boddi prospective 2010 Boddi retrospective 2010	Z = 1.65 <u>Mean</u> 21.33 18.07	8 24 5 (P = 0 <b>DVT</b> 5 9.63 7 11.51	26 96 55, df = .10) <u>Total</u> 3 12 14	31 167 4 (P = <b>C</b> <u>Mean</u> 10.91 14.99	1 174 1474 7 0.07); 1 Controls SD 10.1 10.61	4 26.3 ↓ <b>100</b> .1 <sup>2</sup> = 53% <u>Total</u> 245 112	2% 0% 6 <u>Weight</u> 25.0% 24.0%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42]	Mean Difference IV, Random, 95% CI
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005	Z = 1.65 <u>Mean</u> 21.33 18.07 51	8 24 5 (P = 0 <b>DVT</b> 5 9.63 7 11.51 36.29	26 96 55, df = .10) 7 Total 5 12 14 9 32	31 167 4 (P = <b>C</b> <u>Mean</u> 10.91 14.99 23	1 174 1474 7 0.07); 1 30 50 10.1 10.61 25.92	4 26.3 <b>100.</b> <sup>2</sup> = 53% <b>Total</b> 245 112 229	2% 0% 6 25.0% 24.0% 15.3%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01]	Mean Difference IV, Random, 95% CI
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4	8 24 hi <sup>2</sup> = 8.5 5 (P = 0 <b>DVT</b> 5 9.63 7 11.51 36.29 4 21.7	26 96 55, df = .10) 7 Total 3 12 14 3 22 7 26	31 167 4 (P = 0 <u>Mean</u> 10.91 14.99 23 27.5	1 174 1472 7 0.07); 1 0.07); 1 0.07); 1 10.07 10.1 10.61 25.92 18.2	4 26.2 4 <b>100</b> .4 2 = 53% 5 Total 245 112 229 84	2% 0% 6 25.0% 24.0% 15.3% 20.1%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10]	Mean Difference IV, Random, 95% CI
Velmahos 1998 <b>Total (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 <b>D</b> ) <b>Study or Subgroup</b> Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 brahim 2002	Z = 1.65 <u>Mean</u> 21.33 18.07 51	8 24 hi <sup>2</sup> = 8.5 (P = 0 <b>DVT</b> <b>SE</b> 3 9.63 7 11.51 36.29 4 21.7	26 96 55, df = .10) 7 Total 3 12 14 3 22 7 26	31 167 4 (P = 0 <u>Mean</u> 10.91 14.99 23 27.5	1 174 1474 7 0.07); 1 30 50 10.1 10.61 25.92	4 26.2 4 <b>100</b> .4 2 = 53% 5 Total 245 112 229 84	2% 0% 6 25.0% 24.0% 15.3%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01]	Mean Difference IV, Random, 95% CI
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4	8 24 hi <sup>2</sup> = 8.5 5 (P = 0 <b>DVT</b> 5 9.63 7 11.51 36.29 4 21.7	26 96 55, df = .10) 7 Total 3 12 14 3 22 7 26	31 167 4 (P = 0 <u>Mean</u> 10.91 14.99 23 27.5	1 174 1472 7 0.07); 1 0.07); 1 0.07); 1 10.07 10.1 10.61 25.92 18.2	4 26.2 4 <b>100</b> . 2 = 53% 5 <b>Total</b> 245 112 229 84 174	2% 0% 6 25.0% 24.0% 15.3% 20.1%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81]	Mean Difference IV, Random, 95% CI
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI)	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49	8 24 5 (P = 0 <b>DVT</b> 3 9.63 7 11.51 36.29 4 21.7 9 32	26 96 55, df = .10) 7 Total 12 14 26 26 26 26 26 110	31 167 4 (P = 0 <u>Mean</u> 10.91 14.99 23 27.5 31	1 174 1474 7 0.07); 1 5 0 0.07); 1 5 0 0.07); 1 0.01 10.01 10.01 25.92 18.2 24	4 26.2 4 <b>100</b> . 2 = 53% 5 <b>Total</b> 245 112 229 84 174 <b>844</b>	2% 0% 25.0% 24.0% 15.3% 20.1% 15.6%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81]	Mean Difference IV, Random, 95% CI
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49.	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup>	8 24 5 (P = 0 <b>DVT</b> <b>5</b> 9 9.63 7 11.51 36.29 4 21.7 9 32 = 14.86	26 96 55, df = .10) 7 Total 6 12 14 9 32 7 26 2 26 2 26 2 110 5, df = 4	31 167 4 (P = 0 <u>Mean</u> 10.91 14.99 23 27.5 31	1 174 1474 7 0.07); 1 5 0 0.07); 1 5 0 0.07); 1 0.01 10.01 10.01 25.92 18.2 24	4 26.2 4 <b>100</b> . 2 = 53% 5 <b>Total</b> 245 112 229 84 174 <b>844</b>	2% 0% 25.0% 24.0% 15.3% 20.1% 15.6%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% (C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63]	Mean Difference IV, Random, 95% CI
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 4 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49. Test for overall effect: Z =	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup>	8 24 5 (P = 0 <b>DVT</b> <b>5</b> 9 9.63 7 11.51 36.29 4 21.7 9 32 = 14.86	26 96 55, df = .10) 7 Total 6 12 14 9 32 7 26 2 26 2 26 2 110 5, df = 4	31 167 4 (P = 0 <u>Mean</u> 10.91 14.99 23 27.5 31	1 174 1474 7 0.07); 1 5 0 0.07); 1 5 0 0.07); 1 0.01 10.01 10.01 25.92 18.2 24	4 26.2 4 <b>100</b> . 2 = 53% 5 <b>Total</b> 245 112 229 84 174 <b>844</b>	2% 0% 25.0% 24.0% 15.3% 20.1% 15.6%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% (C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63]	Avours experimental Favours control Mean Difference IV, Random, 95% CI -20 -10 0 10 20
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49. Test for overall effect: Z = (E)	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup> 2.97 (P	8 24 hi <sup>2</sup> = 8.5 i (P = 0 <b>DVT</b> <b>3</b> 9.63 7 11.51 36.29 21.7 32 = 14.86 = 0.003 <b>VT</b>	26 96 55, df = 10) 7 7 7 12 14 32 26 26 26 26 12 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 14 14 14 14 14 14 14 14 14	31 167 4 (P = 0 <u>Mean</u> 10.91 14.99 23 27.5 31 (P = 0.0	1 174 1474 7 0.07); I controls SD 10.1 10.61 25.92 18.2 24 005); I <sup>2</sup> T	4 26.2 4 <b>100</b> . 2 = 53% 5 <b>Total</b> 245 112 229 84 174 <b>844</b> = 73%	2% 0% 25.0% 24.0% 15.3% 20.1% 15.6% 100.0%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63] Risk Ratio	Avours experimental Favours control Mean Difference IV, Random, 95% CI -20 -10 0 10 20 Favours experimental Favours control Risk Ratio
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49. Test for overall effect: Z = (E) Study or Subgroup	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup> 2.97 (P <u>D</u>	8 24 5 (P = 0 <b>DVT</b> 5 9.63 7 11.51 36.29 21.7 32 = 14.86 = 0.003 <b>VT</b> ts To	26 96 55, df = 10) 7 7 7 12 14 32 26 26 26 26 12 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 32 26 14 26 14 26 26 14 26 26 14 26 26 14 26 26 26 26 26 26 26 26 26 26	31 167 4 (P = 0 <u>Mean</u> 10.91 14.99 23 27.5 31 (P = 0.0 (P = 0.0 <b>No DV</b>	1 174 1474 7 0.07); 1 5 5 5 5 7 10.1 10.61 25.92 18.2 24 005); 1 <sup>2</sup> 7 7 7 T Total	4 26.2 4 <b>100</b> .4 2 = 53% 5 <b>Total</b> 245 112 229 84 174 <b>844</b> = 73% Weight	2% 0% 25.0% 24.0% 15.3% 20.1% 15.6% 100.0%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63] Risk Ratio , Random, 95% CI	Avours experimental Favours control Mean Difference IV, Random, 95% CI -20 -10 0 10 20 Favours experimental Favours control Risk Ratio
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49. Test for overall effect: Z = (E) Study or Subgroup Cook 2005	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup> 2.97 (P D <u>Even</u> 1	8 24 ni <sup>2</sup> = 8.5 i (P = 0 <b>DVT</b> 9 9.63 7 11.51 36.29 21.7 3 32 = 14.86 = 0.003 <b>VT</b> ts Tof 7	26 96 55, df = .10) 7 7 7 10 7 12 14 9 26 12 14 9 26 12 14 9 26 12 14 9 26 14 9 26 14 9 26 12 14 9 26 26 12 26 12 26 26 12 26 26 12 26 26 26 26 26 26 26 26 26 2	31 167 4 (P = C Mean 10.91 14.99 23 27.5 31 (P = 0.0 No DV rents 85	I 174 1474 7 0.07); I controls SD 10.1 10.61 25.92 18.2 24 005); I <sup>2</sup> T Total 229	<ul> <li>4 26.2</li> <li>4 100.1</li> <li>2 = 53%</li> <li>5 Total</li> <li>245</li> <li>112</li> <li>229</li> <li>84</li> <li>174</li> <li>844</li> <li>= 73%</li> <li>Weight 59.7%</li> </ul>	2% 0% 5 25.0% 24.0% 15.3% 20.1% 15.6% 100.0%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63] Risk Ratio , Random, 95% CI 1.43 [0.99, 2.06]	Avours experimental Favours control Mean Difference IV, Random, 95% CI -20 -10 0 10 20 Favours experimental Favours control Risk Ratio
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = ( Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49. Test for overall effect: Z = (E) Study or Subgroup Cook 2005 Ibrahim 2002	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup> 2.97 (P D <u>Even</u> 1	8 $24$ $if (P = 0)$ $DVT$ $5 (P = 0)$ $0$ $11.51$ $36.29$ $21.7$ $32$ $= 14.86$ $= 0.003$ $VT$ $ts Tot$ $9$	26 96 55, df = .10) 7 7 7 10 7 12 12 14 32 26 110 5, df = 4 9 110 5, df = 4 9 12 12 12 12 14 12 12 14 12 12 14 12 12 14 12 12 14 12 12 14 12 14 12 14 12 14 12 14 12 14 12 14 12 14 12 14 12 14 12 14 12 14 12 14 14 15 16 16 17 16 17 16 16 17 16 16 17 16 16 17 16 17 16 17 16 16 17 16 17 16 17 16 16 16 16 16 16 16 16 16 16	31 167 4 (P = 0 10.91 14.99 23 27.5 31 (P = 0.0 No DV rents 85 27	I 174 1474 7 0.07); I 10.07); I 10.1 10.61 25.92 18.2 24 005); I <sup>2</sup> T Total 229 84	4 26.: 4 100. 2 = 53% 5 Total 245 112 229 84 174 844 = 73% Weigh 59.7% 21.4%	2% 0% 6 25.0% 24.0% 15.3% 20.1% 15.6% 100.0%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63] Risk Ratio , Random, 95% CI 1.43 [0.99, 2.06] 1.08 [0.58, 1.99]	Avours experimental Favours control Mean Difference IV, Random, 95% CI -20 -10 0 10 20 Favours experimental Favours control Risk Ratio
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = ( Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi prospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49. Test for overall effect: Z = (E) Study or Subgroup Cook 2005 Ibrahim 2002 Joynt 2009	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup> 2.97 (P D <u>Even</u> 1	8 $24$ $i (P = 0)$ $DVT$ $5 (P = 0)$ $0 = 0$ $11.51$ $36.29$ $21.7$ $32$ $= 14.86$ $= 0.003$ $VT$ $ts To$ $7$ $5$	26 96 55, df = .10) 7 7 7 7 9 7 10 12 12 14 32 26 110 5, df = 4 110 5, df = 4 110 5, df = 4 110 12 12 14 12 12 14 12 14 12 12 14 12 12 14 12 14 12 14 12 14 14 12 14 12 14 12 14 14 12 14 14 12 14 14 12 14 14 14 14 15 16 10 10 10 10 10 10 10 10 10 10	31 167 4 (P = C Mean 10.91 14.99 23 27.5 31 (P = 0.0 No DV rents 85 27 18	I 174 1474 7 0.07); I 3 5 5 5 5 7 10.1 10.61 25.92 18.2 24 005); I <sup>2</sup> 7 T Total 229 84 65	4 26.: 4 100. 2 = 53% 5 Total 245 112 229 84 174 844 = 73% Weight 59.79 21.4% 12.0%	2% 0% 6 25.0% 24.0% 15.3% 20.1% 15.6% 100.0% t M-H 6 6	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63] Risk Ratio , Random, 95% CI 1.43 [0.99, 2.06] 1.08 [0.58, 1.99] 1.20 [0.53, 2.72]	Avours experimental Favours control Mean Difference IV, Random, 95% CI -20 -10 0 10 20 Favours experimental Favours control Risk Ratio
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49. Test for overall effect: Z = (E) Study or Subgroup Cook 2005 Ibrahim 2002 Joynt 2009 Kouli 2006	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup> 2.97 (P D <u>Even</u> 1	$ \begin{array}{c} 24 \\ 5i (P = 0) \\ \hline DVT \\ 5i (P = 0) \\ \hline DVT \\ 5i (P = 0) \\ \hline DVT \\ 5i (P = 0) \\ \hline Comparison \\ 11.51 \\ 36.29 \\ 21.7 \\ 36.29 \\ \hline 11.51 \\ 36.29 \\ \hline 21.7 \\ 36.29 \\ \hline 21.7 \\ 36.29 \\ \hline 11.51 \\ 36.29 \\ \hline 21.7 \\ 36.29 \\ \hline 11.51 \\ \hline 11$	26 96 55, df = .10) 7 7 7 7 7 7 7 7 9 7 9 7 7 7 7 7 7 7 7 7 7 7 7 7	31 167 4 (P = 0 10.91 14.99 23 27.5 31 (P = 0.0 No DV rents 85 27	1 174 1474 7 0.07); 1 2 0.07); 1 10.01 10.01 25.92 18.2 24 005); 1 <sup>2</sup> 18.2 24 005); 1 <sup>2</sup> 18.2 24 005); 1 <sup>2</sup> 18.2 24 005); 1 <sup>2</sup>	4 26.2 4 100.1 2 = 53% 5 Total 245 112 229 84 174 844 = 73% Weigh 59.7% 21.4% 12.0% 6.9%	2% 0% 6 25.0% 24.0% 15.3% 20.1% 15.6% 100.0% 100.0%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63] Risk Ratio , Random, 95% CI 1.43 [0.99, 2.06] 1.08 [0.58, 1.99] 1.20 [0.53, 2.72] 1.36 [0.46, 4.01]	Avours experimental Favours control Mean Difference IV, Random, 95% CI -20 -10 0 10 20 Favours experimental Favours control Risk Ratio
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49. Test for overall effect: Z = (E) Study or Subgroup Cook 2005 Ibrahim 2002 Joynt 2009 Kouli 2006 Total (95% CI)	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup> 2.97 (P <u>D</u> Even 1	8 24 112 = 8.5 10 <b>DVT</b> <b>DVT</b> <b>SE</b> 3 9.63 11.51 36.29 21.7 32 = 14.86 = 0.003 <b>VT</b> <b>ts To</b> 5 3 3	26 96 55, df = .10) 7 7 7 7 9 7 10 12 12 14 32 26 110 5, df = 4 110 5, df = 4 110 5, df = 4 110 12 12 14 12 12 14 12 14 12 12 14 12 12 14 12 14 12 14 12 14 14 12 14 12 14 12 14 14 12 14 14 12 14 14 12 14 14 15 16 10 10 10 10 10 10 10 10 10 10	31 167 4 (P = 0 Mean 10.91 14.99 23 27.5 31 (P = 0.0 No DV rents 85 27 18 20	1 174 1474 7 0.07); 1 2 0.07); 1 10.01 10.01 25.92 18.2 24 005); 1 <sup>2</sup> 18.2 24 005); 1 <sup>2</sup> 18.2 24 005); 1 <sup>2</sup> 18.2 24 005); 1 <sup>2</sup>	4 26.: 4 100. 2 = 53% 5 Total 245 112 229 84 174 844 = 73% Weight 59.79 21.4% 12.0%	2% 0% 6 25.0% 24.0% 15.3% 20.1% 15.6% 100.0% 100.0%	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63] Risk Ratio , Random, 95% CI 1.43 [0.99, 2.06] 1.08 [0.58, 1.99] 1.20 [0.53, 2.72]	Avours experimental Favours control Mean Difference IV, Random, 95% CI -20 -10 0 10 20 Favours experimental Favours control Risk Ratio
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49. Test for overall effect: Z = (E) Study or Subgroup Cook 2005 Ibrahim 2002 Joynt 2009 Kouli 2006 Total (95% CI) Total events	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup> 2.97 (P <u>D</u> Even: 1	$8$ $24$ $i = 8.5$ $i (P = 0$ <b>DVT</b> $3 = 9.63$ $7 = 11.51$ $36.29$ $21.7$ $32$ $= 14.86$ $= 0.003$ <b>VT</b> $\frac{15}{5}$ $3$ $34$	26 96 55, df = .10) 7 Total 12 14 26 26 26 12 26 26 14 32 26 14 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 32 26 110 110 110 110 110 110 110 11	31 167 4 (P = 0 Mean 10.91 14.99 23 27.5 31 (P = 0.0 No DV rents 85 27 18 20 150	1 174 1474 1474 10.07); 1 2007); 1 2007); 1 10.1 10.61 25.92 18.2 24 005); 1 <sup>2</sup> 18.2 24 005); 1 <sup>2</sup> 18.2 24 005); 1 <sup>2</sup> 505	4 26.3 4 100.4 2 = 53% 5 Total 245 112 229 84 174 844 = 73% Weigh 59.79 21.49 12.09 6.99 100.09	2% 0% 5 25.0% 24.0% 15.3% 20.1% 15.6% 100.0% t M-H 6 6 6 6	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63] Risk Ratio , Random, 95% CI 1.43 [0.99, 2.06] 1.08 [0.58, 1.99] 1.20 [0.53, 2.72] 1.36 [0.46, 4.01]	Avours experimental Favours control Mean Difference IV, Random, 95% CI -20 -10 0 10 20 Favours experimental Favours control Risk Ratio
Velmahos 1998 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: 2 (D) Study or Subgroup Boddi prospective 2010 Boddi retrospective 2010 Boddi retrospective 2010 Cook 2005 Ibrahim 2002 Velmahos 1998 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 49. Test for overall effect: Z = (E) Study or Subgroup Cook 2005 Ibrahim 2002 Joynt 2009 Kouli 2006 Total (95% CI)	Z = 1.65 <u>Mean</u> 21.33 18.07 51 31.4 49 01; Chi <sup>2</sup> 2.97 (P <u>D</u> Even 1 3 0.00; C	8 $24$ $if (P = 0)$ $DVT$ $5$ $9.63$ $21.7$ $36.29$ $21.7$ $36.29$ $21.7$ $36.29$ $21.7$ $36.29$ $21.7$ $36.29$ $21.7$ $36.29$ $21.7$ $36.29$ $21.7$ $36.29$ $21.7$ $36.29$ $21.7$ $36.29$ $21.7$ $36.29$ $21.7$ $36.29$ $3$	26 96 55, df = 10) <b>Total</b> 12 14 26 26 110 5, df = 4 110 5, df = 4 110 110 110 110 110 110 110 11	31 167 4 (P = 0 Mean 10.91 14.99 23 27.5 31 (P = 0.0 No DV rents 85 27 18 20 150	1 174 1474 1474 10.07); 1 2007); 1 2007); 1 10.01 10.01 25.92 18.2 24 25.92 18.2 24 005); 1 <sup>2</sup> T Total 229 84 65 127 505	4 26.3 4 100.4 2 = 53% 5 Total 245 112 229 84 174 844 = 73% Weigh 59.79 21.49 12.09 6.99 100.09	2% 0% 5 25.0% 24.0% 15.3% 20.1% 15.6% 100.0% t M-H 6 6 6 6	1.73 [0.89, 3.34] 1.64 [0.91, 2.93] Fa Mean Difference IV, Random, 95% C 10.42 [4.83, 16.01] 3.08 [-3.26, 9.42] 28.00 [14.99, 41.01] 3.90 [-5.30, 13.10] 18.00 [5.19, 30.81] 11.22 [3.82, 18.63] Risk Ratio [, Random, 95% CI 1.43 [0.99, 2.06] 1.08 [0.58, 1.99] 1.20 [0.53, 2.72] 1.36 [0.46, 4.01] 1.31 [0.99, 1.74]	Avours experimental Favours control Mean Difference IV, Random, 95% CI -20 -10 0 10 20 Favours experimental Favours control Risk Ratio

Figure 2 - The impact of DVT.

(A) In the ICU on duration of mechanical ventilation; (B) in the ICU on duration of ICU stay; (C) in the ICU on ICU mortality; (D) in the ICU on duration of hospital stay; (E) in the ICU on hospital mortality. DVT: deep vein thrombosis; ICU: Intensive Care Unit.

patients was found to be poor for both proximal and distal DVT, because it depends on the number of pathological compression manoeuvres documented in the ultrasound<sup>27</sup>.

In a prospective cohort study on ICU patients<sup>18</sup>, bilateral lower extremity compression ultrasound was performed within 48 hours of admission to the ICU, twice weekly, and if VTE was clinically suspected. In this study the authors found that the prevalence of DVT was 2.7% on ICU admission, and the incidence was 9.6% during the ICU stay. A recent prospective study that applied the same ultrasound surveillance protocol, substantially confirmed these data<sup>15</sup>. Although the clinical implication of some of these events remains to be established, these results suggest the utility of multiple compression ultrasound examinations during ICU stay.

Since DVT also occurred in patients on mechanical and pharmacological thromboprophylaxis, more effective preventive strategies seem to be necessary to reduce VTE in the critically ill population. However, bleeding complications also occurred relatively frequently in this setting, suggesting that thromboprophylaxis must be carefully considered in these patients. Unfortunately, in a recent large randomised controlled trial, LMWH was not superior to UFH in decreasing the incidence of proximal DVT nor in reducing the incidence of major bleeding complications<sup>28</sup>, although the rate of PE was significantly lower with LMWH than with UFH (1.3 vs 2.3%; hazard ratio, 0.51; 95% CI, 0.30-0.88; p=0.01) The best antithrombotic prophylaxis in this setting does, therefore, remain an unresolved issue.

Our analysis has several limitations: First, we cannot exclude important differences in baseline characteristics and in other concomitant risk factors in patients with and without DVT; thus several other clinical and non-clinical variables could have had an impact on the outcomes, and we could not adjust for them. Second, our systematic review was restricted to case-control studies, and the application of formal meta-analytic methods to observational studies is controversial, since bias implicit in the study design may misrepresent the strength of associations within the data<sup>10</sup>. To minimise this potential bias, we selected only studies in which the diagnosis of DVT was objectively confirmed. Third, the studies included in our meta-analysis had different inclusion and exclusion criteria, and combining results across studies may be inappropriate. However, the heterogeneity between the studies, calculated using the I<sup>2</sup> statistic, was generally low. Furthermore, we decided to perform the analyses using the random-effects model, an approach that accounts for some of the variance between studies. Fourth, since it is recognised that publication bias can

affect the results of meta-analyses, we attempted to assess this potential bias using a funnel plot. Funnel plots that considered ICU mortality and mean hospital stay appeared symmetric, suggesting the absence of publication bias for these two outcomes. However, only a few studies have considered mean duration of mechanical ventilation, mean ICU stay and hospital mortality, and funnel-plot analysis could not be done: the presence of publication bias could not, therefore, be excluded for these three outcomes. Fifth, we were unable to perform an adjusted analysis accounting for difference in baseline characteristics and concomitant risk factors (other than DVT) that may contribute to length of stay and mortality among critically ill patients since the contributing studies did not uniformly present data required for such an analysis. This may have led to an overestimate of the WMD and RR estimates for these outcomes. Sixth, our study assumes that ultrasonography is the reference standard for the diagnosis of DVT in critically ill patients; although the reliability of ultrasonography in the ICU has not been tested, it is the dominant method of screening and diagnosis in this setting<sup>27</sup>. Finally, we cannot conclude that DVT is an independent risk factor for poor outcomes in ICU patients because we did not obtain individual patients' data from single studies. Despite these limitations, the findings of the present meta-analysis are clinically important, at least insofar as they highlight the (largely undiagnosed) burden of disease attributable to VTE in critically ill patients. They point to the need for further studies in this area, and to the need for more effective strategies to prevent, diagnose and manage DVT in critically ill patients.

#### Conclusions

In summary, to the best of our knowledge, this is the first systematic review and meta-analysis of the literature investigating the effects of DVT in critically ill patients. Although the strength of our conclusions about the impact of DVT on critically ill patients is limited by the quality of the contributing data and the paucity of eligible studies with control subjects, it is clear that patients who experience DVT have significantly higher rates of morbid outcomes, highlighting the need for further research in this area.

## **Authors' contributions**

AM, YK and FD extracted, reviewed and statistically evaluated the primary data. AM, MN, FD and SS take primary responsibility for the manuscript. MN, SS, FF, MB and GFG re-evaluated the data and revised the manuscript.

The Authors declare no conflict of interest

#### References

- Cook D, Attia J, Weaver B, et al. Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. J Crit Care 2000; 15: 127-32.
- Gando S, Kameue T, Nanzaki S, et al. Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome. Crit Care Med 1997; 25: 1820-6.
- Crowther MA, Cook DJ, Griffith LE, et al. Neither baseline tests of molecular hypercoagulability nor D-dimer levels predict deep venous thrombosis in critically ill medicalsurgical patients. Intensive Care Med 2005; 31: 48-55.
- Crowther MA, McDonald E, Johnston M, et al. Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. Blood Coagul Fibrinolysis 2002; 13: 49-52.
- 5) Ginsberg JS, Kearon C, Douketis J, et al. The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis. Arch Intern Med 1997; **157**: 1077-81.
- Cook D, Douketis J, Crowther MA, et al. The diagnosis of deep venous thrombosis and pulmonary embolism in medicalsurgical intensive care unit patients. J Crit Care 2005; 20: 314-9.
- Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995; 274: 335-7
- Cook DJ, Crowther MA, Meade MO, et al. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care 2005; 20: 309-13.
- McGinn T, Wyer PC, Newman TB, for the Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ 2004; 171: 1369-73.
- 10) Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 2000; 283: 2008-12.
- 11) Wells G, Shea B. Data extraction for nonrandomised systematic reviews. University of Ottawa, Ottawa. Available at: http://www.ohri.ca/programs/clinical\_epidemiology/ oxford.htm. Accessed on 30/12/2014.
- De Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
- Higgins JP, Thompson SG, Deeks JJ. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-60.
- 14) Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. Br Med J 2001; 323: 101-5.
- 15) Patel R, Cook DJ, Meade MO, et al. Burden of illness in venous thromboembolism in critical care: a multicenter observational study. J Crit Care 2005; 20: 341-7.
- 16) Boddi M, Barbani F, Abbate R, et al. Reduction in deep vein thrombosis incidence in intensive care after a clinician education program. J Thromb Haemost 2010; 8: 121-8.
- 17) Joynt GM, Li TS, Griffith JF, et al. The incidence of deep venous thrombosis in Chinese medical intensive care unit patients. Hong Kong Med J 2009; 15: 24-30.
- 18) Khouli H, Shapiro J, Pham VP. Efficacy of deep venous thrombosis prophylaxis in the medical intensive care unit. J Intensive Care Med 2006; 21: 352-8.
- 19) Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005; 33: 1565-71.

- 20) Major KM, Wilson M, Nishi GK, et al. The incidence of thromboembolism in the surgical intensive care unit. Am Surg 2003; 69: 857-61.
- 21) Ibrahim EH, Iregui M, Prentice D, et al. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 2002; **30**: 771-4.
- 22) Velmahos GC, Nigro J, Tatevossian R, et al. Inability of an aggressive policy of thromboprophylaxis to prevent deep venous thrombosis (DVT) in critically injured patients: are current methods of DVT prophylaxis insufficient? J Am Coll Surg 1998; 187: 529-33.
- 23) Cafferata HT, Morrison S, Duer C, et al. Venous thromboembolism in trauma patients: standardized risk factors. J Vasc Surg 1998; **28**: 250-9.
- 24) Crowther MA, Cook DJ, Griffith LE, et al. Deep venous thrombosis: clinically silent in the intensive care unit. J Crit Care 2005; **20**: 334-40.
- 25) Mckelvie PA: Autopsy evidence of pulmonary thromboembolism. Med J Australia 1994; **160**: 127-8.
- 26) Schelling SM, Beyer J, Kakkar AK, et al. Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. J Thromb Haemost 2007; 5: 1431-7.
- 27) Schellong S, Hesselschwerdt HJ, Paar WD, et al. Rates of proximal deep vein thrombosis as assessed by compression ultrasonography in patients receiving prolonged thromboprophylaxis with low molecular weight heparin after major orthopedic surgery. Thromb Haemost 2005; 94: 532-6.
- 28) PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011; 364: 1305-14.

Arrived: 30 October 2014 - Revision accepted: 28 January 2015 Correspondence: Alessandra Malato Cattedra ed U.O. di Ematologia con Trapianto Azienda Ospedaliera Universitaria Policlinico "P. Giaccone" Via del Vespro 12 90127 Palermo, Italy e-mail: alessandramalato@hotmail.com